#United States #Los Angeles #Schall Law Firm #Securities Fraud #Capricor Therapeutics

Investors Encouraged to Join Lawsuit Against Capricor Therapeutics

The Schall Law Firm has issued a reminder to investors regarding a potential class action lawsuit involving Capricor Therapeutics, Inc. This case arises from assertions that the company has committed violations of the Securities Exchange Act, specifically Sections 10(b) and 20(a), along with SEC Rule 10b-5. The lawsuit relates to Capricor's activities between October 9, 2024, and July 10, 2025, which includes a critical period during which the company allegedly misrepresented important information to shareholders.

Overview of the Allegations

According to the allegations, Capricor has made misleading statements concerning its efforts to secure FDA approval for its drug candidate, deramiocel. This includes claims of a successful mid-cycle review devoid of major deficiencies, alongside plans for an advisory committee meeting. However, the lawsuit indicates that the company was hiding negative data from the Phase 2 HOPE-2 trial. These misleading communications may have impacted stock value and led to significant losses for investors once the true situation came to light.

Why Investors Should Act Now

Investors who purchased shares during the outlined period are encouraged to act promptly and engage with Schall Law Firm before September 15, 2025, to discuss their potential involvement in this lawsuit. This is particularly critical for anyone who may have suffered a financial loss as a result of Capricor's actions. The law firm is dedicated to representing shareholder rights and specializes in securities class action cases.

If you would like to discuss your legal rights more comprehensively, you are invited to contact Brian Schall directly at their Los Angeles office. This consultation is provided free of charge, allowing shareholders to understand their options without any monetary commitment.

Class Action Status

It's important to note that the class action has not yet been certified, which means that until such certification occurs, affected investors are not represented by an attorney. Shareholders who choose not to engage with the process may find themselves categorized as absent class members, missing out on potential recovery opportunities.

Conclusion

The developments surrounding Capricor Therapeutics remind us of the importance of transparency and integrity in the public markets. As the situation unfolds, affected investors are encouraged to seek legal guidance promptly to safeguard their interests. Joining this class action may provide a vital avenue for recovery and accountability within the financial landscape. For more information, reach out through the Schall Law Firm website or their contact number. Stay informed about your rights and do not hesitate to assert them in the face of misleading corporate practices.